Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Peptic ulcer disease (in combination with antibiotics for *H. pylori* eradication)
## Adult Dosing
* **GERD:** 20 mg or 40 mg orally or intravenously once daily.
* **Erosive esophagitis:** 40 mg orally or intravenously once daily. Healing typically requires 4 to 8 weeks of treatment.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally or intravenously twice daily, may be increased as needed. Doses up to 240 mg daily have been administered intravenously.
* ***H. pylori* eradication (part of triple therapy):** 40 mg orally twice daily for 7 to 14 days.
## Pediatric Dosing
* **GERD and erosive esophagitis (ages 5 to 16 years):** 20 mg or 40 mg orally once daily. The choice of dose depends on the severity of the condition.
* Dosing for children under 5 years of age is not well-established and requires careful consideration and often specialist guidance.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, other PPIs, or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and fatigue. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Certain antifungals (e.g., ketoconazole, itraconazole):** Pantoprazole can decrease absorption due to reduced gastric acidity.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Warfarin:** May increase INR and risk of bleeding. Monitor INR closely.
* **Rilpivirine, Atazanavir:** Coadministration with PPIs is generally not recommended due to potential subtherapeutic levels of these antivirals.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, muscle cramps, seizures).
* Consider monitoring vitamin B12 levels with long-term therapy.
* Monitor for fracture risk with prolonged use.
* Monitor for *C. difficile* infection.
## Clinical Pearls
* Administer oral pantoprazole 30 to 60 minutes before a meal.
* For IV administration, reconstitute and dilute as per manufacturer instructions; infusion rate is typically over 15 minutes.
* While generally well-tolerated, long-term use should be reserved for conditions requiring ongoing acid suppression.
***
**Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information with the official product monograph or a reliable drug information resource before making clinical decisions.
